Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
2
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
akcea therapeutics
alnylam pharmaceuticals
biotech
brexanalone
clinical data
depression
drugs
european medicines agency
fda
harvard pilgrim health care
hereditary transthyretin amyloidosis
inotersen
institute for clinical and economic review
jeff jonas
major depressive disorder
mental illness
neuroscience
new york blog main
new york top stories
onpattro
patisiran
pfizer
phase 3 trial
postpartum depression
psychiatric disorders
sage therapeutics
san diego blog main
san diego top stories
tafamidis
What
drug
2
×
fda
hits
2
×
alnylam
approval
approves
brexanalone
cells
depression
ema
employ
europe
follows
gene
harmful
hour
infusion
interference
make
mark
medical
medicine
method
mute
phase
postpartum
ppd
protein
rna
rnai
sage
soon
stock
supervised
surges
therapeutics
trial
uses
way
win
Language
Current search:
boston
×
drug
×
hits
×
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
